Bergen, Norway, May, 19 2017 – Leading oncology biopharmaceutical company BerGenBio ASA, announces that its first-in-class small molecule Axl inhibitor BGB324 will be featured in a poster presentation at the upcoming 2017 American Society of Clinical Oncology (ASCO) annual meeting in Chicago, IL from June 2-6, 2017. The presentation will focus on pre-clinical as well as clinical activity of BGB324 in high-risk Myeloid Dysplastic Syndrome (MDS).
The details of the poster presentation are as follows:
Blockade of Axl with the small molecule inhibitor BGB324 shows activity in vitro and in patients with high-risk MDS.
? Poster Session: Hematologic Malignancies—Leukemia, Myelodysplastic Syndromes, and Allotransplant
? Abstract number: 7059
? Monday Jun 5, 2017 8:00 AM - 11:30 AM (CT)
Further details can be found at http://abstracts.asco.org/.
About MDS
MDS refers to a range of conditions that can occur when the blood-forming cells in the bone marrow are damaged, interfering with the making of new blood cells. In about one-third of patients, MDS can progress into AML. Treatment typically consists of supportive therapy and may include bone marrow stimulation, hypomethylating agents and cytotoxic chemotherapy. Existing therapies are particularly inadequate in patients with high risk MDS, who have a median survival of five months .
About ASCO
From June 2 to June 6 2017, over 30,000 oncology professionals from around the globe will meet in Chicago, IL, to discuss the latest advances in cancer therapy during the 2017 ASCO Annual Meeting, organised by the American Society Of Clinical Oncology (ASCO).
About BerGenBio ASA
BerGenBio (Bergen, Norway) is a clinical-stage biopharmaceutical company focused on developing a pipeline of first-in-class Axl kinase inhibitors to treat multiple cancer indications. The Company is a world leader in understanding the central role of Axl kinase in promoting cancer spread, immune evasion and drug resistance in multiple aggressive haematological and solid cancers.
BerGenBio’s lead product, BGB324, is a selective, potent and orally bio-available small molecule Axl inhibitor in Phase II clinical development in three major cancer indications. It is the only selective Axl inhibitor in clinical development. BGB324 is being developed by BerGenBio as a single agent therapy in acute myeloid leukaemia (AML)/myeloid dysplastic syndrome (MDS) and in combination with TARCEVA® (erlotinib) in advanced non-small-cell lung cancer (NSCLC); and in combination with KEYTRUDA® (pembrolizumab) in advanced NSCLC and triple negative breast cancer (TNBC) in collaboration with Merck & Co. Inc. (MSD).
The Company is also developing a diversified pre-clinical pipeline of selective Axl inhibitors including BGB149, anti-Axl monoclonal antibody.
For further information, please visit: www.bergenbio.com
KEYTRUDA® is a registered trademark of Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc. TARCEVA® is a registered trademark of OSI Pharmaceuticals, LLC., marketed by Roche-Genentech.
-Ends-
Contacts
Richard Godfrey
CEO, BerGenBio ASA
+47 917 86 304
David Dible, Mark Swallow, Marine Perrier
Citigate Dewe Rogerson
bergenbio@citigatedr.co.uk ?
+44 207 638 9571
